In lung cancer patients, EGFR mutations are generally exclusive with KRAS and BRAF mutations, and tumors with either KRAS (15–25%) or BRAF (2-3%) mutations are relatively insensitive to EGFR TKIs [8, 9]. Here, KRAS is linked to lung carcinoma.